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ttp://dx.doi.org/10.1016/j.jmoldx.2012.09.002Inherited cardiomyopathies include hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhyth-
mogenic right ventricular cardiomyopathy, left ventricular noncompaction, and restrictive cardiomy-
opathy. These diseases have a substantial genetic component and predispose to sudden cardiac death,
which provides a high incentive to identify and sequence disease genes in affected individuals to
identify pathogenic variants. Clinical genetic testing, which is now widely available, can be a powerful
tool for identifying presymptomatic individuals. However, locus and allelic heterogeneity are the rule,
as are clinical variability and reduced penetrance of disease in carriers of pathogenic variants. These
factors, combined with genetic and phenotypic overlap between different cardiomyopathies, have made
clinical genetic testing a lengthy and costly process. Next-generation sequencing technologies have
removed many limitations such that comprehensive testing is now feasible, shortening diagnostic
odysseys for clinically complex cases. Remaining challenges include the incomplete understanding of
the spectrum of benign and pathogenic variants in the cardiomyopathy genes, which is a source of
inconclusive results. This review provides an overview of inherited cardiomyopathies with a focus on
their genetic etiology and diagnostic testing in the postgenomic era. (J Mol Diagn 2013, 15: 158e170;
http://dx.doi.org/10.1016/j.jmoldx.2012.09.002)P.T. and M.A.K. contributed equally to this work.Inherited cardiomyopathies are a group of cardiovascular
disorders classiﬁed based on ventricular morphology and
function and include hypertrophic cardiomyopathy (HCM),
dilated cardiomyopathy (DCM), arrhythmogenic right ven-
tricular cardiomyopathy (ARVC), left ventricular noncom-
paction (LVNC), and restrictive cardiomyopathy (RCM).1 Of
these, HCM is the most common, with an estimated preva-
lence of 1 in 500 individuals. Common complications can
include heart failure and sudden cardiac death (SCD), and
undiagnosed disease (particularly in HCM and ARVC)stigative Pathology
.accounts for a signiﬁcant proportion of SCD in young adults
and athletes.2
Since the discovery that pathogenic variants in the
sarcomere genes cause HCM,3 many advancements have
been made to deﬁne the genetic etiology of inherited
cardiomyopathies. The increased risk of SCD in individuals
with disease encouraged interest in clinical genetic testing,
which began approximately a decade ago and is now widely
Genetic Testing for Cardiomyopathiesavailable through genetic testing laboratories in the United
States and worldwide (http://www.genetests.org and http://
www.ncbi.nlm.nih.gov/gtr). However, the high degree of
locus and allelic heterogeneity that is characteristic of all
cardiomyopathies necessitates sequence analysis of the
entire coding region of multiple genes, which has been
a costly and lengthy process using traditional technologies.
Growing genetic and phenotypic overlap among different
cardiomyopathies adds further complexity, often resulting in
stepwise testing of multiple disease-speciﬁc gene panels
when the diagnosis is not entirely clear. Next-generation
sequencing (NGS) technologies have removed these
barriers and enabled testing of a large number of genes
simultaneously. NGS-based test panels are now offered by
a growing number of diagnostic laboratories worldwide,
which is beginning to change the landscape of medical
genetic testing. However, an unwelcome effect of this
unprecedented ability to sequence any gene is an increased
likelihood of detecting variants of unclear clinical signiﬁ-
cance (VUSs). This effect necessitates a stringent review of
the evidence supporting claims of disease association as
variants in insufﬁciently studied genes can be difﬁcult to
interpret. For example, variants in >50 genes have been
reported to be causative for various inherited cardiomyop-
athies, but a detailed review and assignment of a conﬁdence
level shows that only half of them meet the criteria to be
considered a deﬁnitive disease gene (Table 1).
Practice guidelines and expert opinions on clinical
management and genetic testing for inherited cardiomyopa-
thies recommend taking a detailed family history that
includes at least three generations, clinically screening at-risk
family members, counseling patients on a possible inherited
cause, and considering genetic testing of the most clearly
affected person in the family.4,5 However, current guidelines
recommend comprehensive or targeted genetic testing for
only a small number of genes.4 This is in contrast to the
increasing use of large gene panels in clinical practice.
For inherited cardiomyopathies, therapeutic options are
limited, and, thus, the clinical utility of genetic testing
largely lies in the ability to establish or conﬁrm the disease
etiology in the proband (when a deﬁnitively pathogenic
variant is identiﬁed). Subsequent testing of at-risk family
members can remove the disease risk (when negative)
or identify those in need of clinical monitoring or inter-
vention to decrease the risk of morbidity or mortality (when
positive). However, because genetic testing for inherited
cardiomyopathies is a relatively young discipline, the spec-
trum of pathogenic variants present in the population is
incompletely characterized, even in well-established disease
genes. This leaves a high probability of detecting a novel
sequence VUS, which can create substantial emotional
difﬁculties for patients.
This review summarizes the clinical features of in-
herited cardiomyopathies, current knowledge on the
genetic etiologies, and clinical genetic testing in the
postgenomic era.The Journal of Molecular Diagnostics - jmd.amjpathol.orgHypertrophic Cardiomyopathy
Clinical Description and Disease Mechanism
HCM is characterized by left ventricular hypertrophy (LVH) in
the absence of an underlying systemic condition or other
cardiac disease, such as valvular heart disease or hypertension.
With an estimated prevalence of 1 in 500 in the general pop-
ulation,6,7 HCM is the most common inherited heart condition
and the leading cause of sudden nontraumatic death in young
adults and competitive athletes in the United States.8 Although
the age at onset of HCM can range from infancy to old age,
manifestations usually do not appear before adolescence in
carriers of a pathogenic variant.8 HCM is primarily inherited in
an autosomal dominant pattern, although reduced penetrance
and clinical variability are common. Clinical manifestations
range from being completely asymptomatic to progressive
heart failure and SCD caused by mechanical or electrical
defects. HCM is traditionally diagnosed using cardiac imaging
modalities, such as echocardiography and cardiac magnetic
resonance imaging, and often presents as asymmetrical septal
hypertrophy.9 A complete list of features associated with
classic HCM is shown in Supplemental Table S1. Histopath-
ologic hallmarks include myocyte hypertrophy and disarray
and increased myocardial ﬁbrosis (for a comparison of normal
cardiac histology and a heart with HCM showing disarray and
ﬁbrosis see the article by Cirino and Ho9). These lesions ulti-
mately lead to impaired diastolic function.10 In a small
proportion of patients (w5% to 10%), cardiac function
worsens over time, leading to progressive LV dilatation, heart
failure, and, ultimately, burnt-out HCM, which is morpholog-
ically similar to DCM.11
HCM is frequently described as a disease of the sarcomere,
and pathogenic variants have been detected in almost all sarco-
mere proteins.3 Molecular mechanisms include increased actin-
activatedATPase activity, disruptionof actin-myosin interaction
and force generation, and altered intracellular calcium signaling
in cardiomyocytes.12 In addition, some data suggest that LVH
can be caused by perturbations of transforming growth factor
b and CaMKII Mef2 signaling pathways.13
The differential diagnosis of HCM includes several
syndromes that typically manifest with multiorgan involve-
ment but that can also present with isolated or predominant
LVH. These syndromes include metabolic (storage) cardio-
myopathies, such as Danon disease and Wolff-Parkinson-
White syndrome,14 and the lysosomal storage disorder Fabry
disease.15 LVH in these conditions is not accompanied by
myocyte disarray or ﬁbrosis but by a characteristic accumu-
lation of glycogen or glycosphingolipids in cellular vacu-
oles.14 LVH is also a part of the phenotypic spectrum of
Noonan syndrome16 and Friedreich ataxia.17Genetic Etiology and Clinical Testing
Pathogenic variants for HCM have been described in eight
genes encoding sarcomere proteins,withmost (w80%)present159
Table 1 Cardiomyopathy Genes and Associated Clinical Features
Gene
Evidence
level*
Spectrum of clinical features
Inheritance Location/rolezHCM DCM ARVC LVNC RCM Other cardiovascular/musculary
ABCC9 3 X AD Potassium channelx
ACTC1 1 X{ X X X AD Sarcomere
ACTN2 2 X{ X AD Z-disk
ANKRD1 3 X X IU Z-disk
BAG3 2 Xk X{ Xk Myofibrillar myopathyk AD Z-disk
CASQ2 1 X CPVT{ AR Sarcoplasmic reticulum
CAV3 3 X X Myopathies, long QT, hyperCKemia AD, AR, IU Plasma membrane
CRYAB 1 X Myofibrillar myopathy{ AD, AR, IU Chaperone
CSRP3 2 X{ X Myopathy AD Z-disk
CTF1 3 X IU Cytokinex
DES 2 X{ X X Myofibrillar myopathy AD Intermediate filament
DSC2 1 X X{ AD Desmosome
DSG2 1 X X{ AD Desmosome
DSP 1 X X{ Carvajal syndrome{ AD, AR Desmosome
DTNA 2 X{ AD Dystrophin-associated
protein complex
EMD 1 Xk Emery-Dreifuss muscular
dystrophy{k
XL Nuclear membrane
FHL2 3 X IU Z-disk
GATAD1 2 X{ AR Unknownx
GLA 1 Xk Fabry disease{k XL Lysosomex
JUP 2 X{ Naxos disease{ AD, AR Desmosome
LAMA4 3 X IU Basement membrane
LAMP2 1 X X Danon disease{ XL Lysosomex
LDB3 2 X X{ X Myofibrillar myopathy AD Z-disk
LMNA 1 X{ X Myopathies, muscular and
lipodystrophies
AD Nuclear membrane
MYBPC3 1 X{ X X AD Sarcomere
MYH6 3 X X CHD AD Sarcomere
MYH7 1 X{ X X X Myopathies AD Sarcomere
MYL2 1 X{ AD Sarcomere
MYL3 1 X{ AD Sarcomere
MYLK2 3 X IU Kinasex
MYOZ2 2 X{ AD Z-disk
NEBL 3 X Endocardial fibroelastosis IU Z-disk
NEXN 3 X X AD Z-disk
PKP2 1 X X{ AD Desmosome
PLN 1 X X{ AD Sarcoplasmic reticulum
PRKAG2 1 Xk WPW, glycogen storage disease{k AD Kinasex
PSEN2 3 X IU Transmembrane proteinx
RBM20 1 X{ AD RNA-binding proteinx
RYR2 1 X X CPVT{ AD Sarcoplasmic reticulum
SCN5A 1 X{ Brugada syndrome,{ long QT{ AD Sodium channel
SGCD 1 Xk Limb-girdle muscular dystrophy{ AR, AD, IU Dystrophin-associated
protein complex
TAZ 1 Xk Xk Barth syndrome{k XL Mitochondriumx
TCAP 2 X Xk Limb-girdle muscular dystrophy{k AR, AD, IU Z-disk
TMEM43 1 X{ AD Transmembrane proteinx
TMPO 3 X IU Nuclear membrane
TNNC1 2 X X{ AD Sarcomere
TNNI3 1 X{ X X AD Sarcomere
TNNT2 1 X{ X X X AD Sarcomere
TPM1 1 X{ X AD Sarcomere
TTN 1 X X{ X Myopathies AD Sarcomere
TTR 1 Xk Amyloidosis{k AD Transport proteinx
VCL 3 X X{ X AD Z-disk
Teekakirikul et al
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Genetic Testing for Cardiomyopathiesin theMYH7 andMYBPC3 genes (Table 1).1,3 As is typical for
structural proteins, most sarcomere variants are believed to act
in a dominant negative manner (ie, by adversely affecting the
normal gene product). Loss-of-function variants leading to
haploinsufﬁciency occur less frequently but are prevalent in
the MYBPC3 gene.18 Collectively, sarcomere variants are
identiﬁed in up to 60% of patients with HCM who also have
a family history and in w40% of patients with sporadic
HCM.19 Storage cardiomyopathies masquerading as HCM are
caused by mutations in LAMP2 (Danon disease), PRKAG2
(Wolff-Parkinson-White syndrome), and GLA (Fabry disase).
Recently, the spectrum of genes associated with HCM has
been expanded to nonsarcomeric genes and includes genes
encoding Z-disk proteins and proteins located in the sarco-
plasmic reticulum and plasma membrane (Table 1). However,
variants in these genes are rare, and studies providing
evidence of a role in disease are limited. Some genes are
associated by strong genetic evidence, such as segregation
with disease or in vivo functional data (eg, CSRP3),20 but
many genes (eg, MYH6, MYLK2, and TCAP) are supported
only by the presence of variants in affected individuals,
absence from controls, and perhaps computational assess-
ments. These genes are better described as candidate genes
(Table 1). Although almost 1000 variants for HCM have been
identiﬁed to date,19 most are private and can, therefore, be
detected only through comprehensive genetic testing. A small
number of recurring variants are present at higher population
frequencies, the most common of which is a 25-bp deletion in
intron 32 of the MYBPC3 gene, which is prevalent in South-
east Asian populations (w4%), accounting for an increased
risk of heart failure with an odds ratio ofw7.21
With few exceptions, genotype-phenotype correlations
for HCM are incompletely deﬁned. Those that have been
established are broad correlations at the gene level. For
example, some, but not all, TNNT2 mutations are associated
with only minor hypertrophy but an appreciable risk of
arrhythmia.22 MYH7 variants generally seem to lead to
signiﬁcant LVH by the second decade of life and are
thought to be associated with an increased risk of heart
failure and SCD.23 In contrast, pathogenic variants in
MYBPC3 are believed to be associated with a later age at
onset,24 although they have also been identiﬁed in a signif-
icant proportion of patients with childhood-onset LVH.25
Most MYBPC3 variants in these pediatric patients were
missense changes, which contrasts with the high prevalence*Genes were classiﬁed into three levels with increasing evidence supporting a
absent from a large number of controls. Level 1: multiple studies, variants, and fa
few studies, variants, and families reported and limited segregation observed. Lev
not established.
yAdditional cardiovascular or muscular features/conditions with or without car
xLocation not depicted in Figure 1. Additional references used to arrive at the
{Disease association serving as the primary basis for evidence level.
kCardiomyopathy seen as part of a larger disease spectrum (disease noted).
AD, autosomal dominant; AR, autosomal recessive; CPVT, catecholaminerg
IU, inheritance unknown; WPW, Wolff-Parkinson-White syndrome; X, disease/gen
The Journal of Molecular Diagnostics - jmd.amjpathol.orgof loss-of-function variants identiﬁed in the adult HCM
population and suggests that missense variants may have
more severe functional consequences.25
Recent clinical guidelines for HCM recommend compre-
hensive testing for ﬁve HCM genes (MYBPC3, MYH7,
TNNI3, TNNT2, and TPM1).4 Sequencing panels including,
but not limited to, these genes are offered by several labo-
ratories in the United States and worldwide (http://www.
genetests.org and http://www.ncbi.nlm.nih.gov/gtr).
Currently, genetic testing for HCM is primarily used
to identify families with a detectable genetic cause of disease
and to screen at-risk family members. Testing can also help
rule out nongenetic conditions, such as athlete’s heart,
although only when a pathogenic variant is identiﬁed.19,26
Owing to the lack of clear genotype-phenotype correlations,
the use of genetic test results in guiding clinical management
is limited. A notable exception is enzyme replacement therapy
for storage disorders that can present as isolated LVH.27
An emerging area is the use of genotype data to guide
therapeutic decisions in preclinical individuals. Animal studies
suggest that calcium channel blockers, such as diltiazem, may
delay the clinical progression of disease, and clinical trials are
currently under way.28 In addition, animal studies have shown
evidence of a link between sarcomeric HCM and increased
transforming growth factor b signaling. An antietransforming
growth factor b antibody and losartan (an angiotensin II
receptor type 1 antagonist) prevented cardiac ﬁbrosis and
hypertrophy in sarcomeremutationepositivemice,whichmay
open additional therapeutic avenues.13
Dilated Cardiomyopathy
Clinical Description and Disease Mechanism
DCM is deﬁned by LV dilatation and systolic dysfunction
(a reduction in myocardial force generation characterized by
an ejection fraction of <50%) and is the most common
indication for cardiac transplantation in the United States, as
reviewed by Hershberger et al.29 The spectrum of clinical
manifestations includes heart failure, thromboembolism, and
SCD. DCM can also be an end-stage presentation of other
diseases or environmental exposures, including myocarditis
and alcohol abuse. Idiopathic DCM, which is diagnosed
when known systemic or environmental triggers have been
excluded, includes genetic DCM. The estimated prevalencerole in disease based on the following criteria. All reported variants were
milies reported and segregation with disease established. Level 2: single or
el 3: single or few studies, variants, and families reported and segregation
diomyopathy.zLocation or role of gene depicted in Figure 1.
evidence levels are available on request.
ic polymorphic ventricular tachycardia; CHD, congenital heart disease;
e association; XL, X-linked.
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Teekakirikul et alof idiopathic DCM is 1 in 2500 individuals, although this may
be an underestimate, and the percentage of idiopathic DCM
cases that have a genetic etiology is estimated to be 30% to
50% based on the presence of a family history.29 The age at
onset can vary from childhood to late adulthood, although
most patients are diagnosed between 20 and 50 years of age.30
In contrast to HCM, myocyte disarray is absent, although
myocyte hypertrophy and increased ﬁbrosis may be
observed.31 Unlike HCM, contractile dysfunction and
ventricular remodeling in DCM are typically progressive.
Although penetrance is age dependent and incomplete,
earliest overt DCM is characterized by isolated LV dilatation
and/or mild LV systolic dysfunction. The histopathologic
features of this stage have not been well described. Over
a varying amount of time, LV remodeling continues and may
progress to severe dilatation and systolic dysfunction with
nonspeciﬁc histopathologic features of myocyte hypertrophy
and interstitial ﬁbrosis. Ventricular remodeling may culmi-
nate in fatal end-stage heart failure, arrhythmia, or a car-
dioembolic event (eg, stroke). Nevertheless, robust natural
history studies do not exist to inform the rate or likelihood of
progression from mild to severe disease.
DCM can also present with muscular involvement and
may be the presenting or primary clinical feature of several
multisystemic conditions, including Emery-Dreifuss mus-
cular dystrophy, Barth syndrome, myoﬁbrillar myopathy,
and Duchenne’s muscular dystrophy. Furthermore, the
spectrum of genetic DCM has recently been expanded to
include peripartum cardiomyopathy based on familial co-
occurrences of peripartum cardiomyopathy and DCM.32
Compared with HCM, which is mainly a disease of the
sarcomere, DCM shows a considerably higher degree of
locus heterogeneity with a steadily growing number of
genes implicated (currently w40) (Table 1). These genes
are part of a functional continuum that includes the sarco-
mere, Z-disk, nuclear lamina proteins, intermediate ﬁla-
ments, and the dystrophin-associated glycoprotein complex
(Figure 1).33 Molecular mechanisms include diminished
force generation and transmission, alterations of energy
production and regulation, and intracellular calcium defects,
as reviewed by Watkins et al.34 As is true for all cardio-
myopathies, DCM is most commonly inherited in an auto-
somal dominant pattern, although X-linked and autosomal
recessive inheritances have been described.
Genetic Etiology and Clinical Testing
Owing to signiﬁcant locus and allelic heterogeneity, genetic
testing for DCM is only now becoming more widely used in
clinical practice, and, therefore, the variant spectrum and
detection rates are less deﬁned than are those for HCM. It is
estimated that pathogenic variants can be identiﬁed in 17%
to 30% of individuals with DCM when up to 20 genes are
sequenced. Unlike for HCM, most DCM genes contribute
only a small percentage of all pathogenic variants.35e38
Clear genotype-phenotype correlations are rare. Exceptions162include variants in the LMNA and SCN5A genes, which are
typically associated with DCM and conduction system
disease.39,40 The electrophysiologic manifestations usually
appear before the onset of DCM and may be the only
cardiac features.41 Recent evidence suggests that desmo-
somal genes, traditionally known to cause ARVC, may also
be involved in the etiology of DCM,42,43 and new genes for
DCM are continually being discovered, with recent addi-
tions including the gene encoding BCL2eassociated atha-
nogene 3 (BAG3), RBM20, and titin (TTN) (Table 1). TTN
may contribute up to 25% of familial and 18% of sporadic
DCM cases,44 making it by far the most commonly mutated
gene in DCM and potentially elevating the detection rate of
genetic testing panels to that of HCM.
Current guidelines have not yet incorporated these recent
discoveries and recommend comprehensive testing for the
LMNA and SCN5A genes in patients with DCM who also
have signiﬁcant cardiac conduction disease and/or a family
history of premature SCD.4 Genetic testing can allow for
informed family evaluations if a pathogenic variant is
identiﬁed in the proband. In addition, there is evidence that
patients with asymptomatic systolic dysfunction beneﬁt
from pharmacologic treatment.45
Arrhythmogenic Right Ventricular
Cardiomyopathy
Clinical Description and Disease Mechanism
ARVC is deﬁned by myocyte loss and ﬁbrofatty inﬁltration
of the myocardium is associated with an increased suscepti-
bility to arrhythmias and sudden death and accounts for
a signiﬁcant portion of sudden deaths in athletes and young
adults.46 Initially thought to affect only the right ventricle,
LV involvement is now becoming increasingly recognized.47
The prevalence of ARVC is estimated to be 1 in 2000 to 5000
individuals, with 30% to 50% of cases being familial.48
ARVC is typically inherited in an autosomal dominant
pattern with reduced penetrance and variable expressivity
and affects men more frequently than women.49 Often
appearing in young adults, 80% of cases are diagnosed
before 40 years of age. Beginning in 1994, an international
task force established criteria for a clinical diagnosis of
ARVC based on electrocardiographic ﬁndings (repolariza-
tion, depolarization, or conduction abnormalities), the pres-
ence of arrhythmias, structural defects, histopathologic
features, and familial features. These criteria, revised in 2010,
are divided into six categories with major and minor features,
and an individual is considered to meet the task force criteria
for ARVCwhen two major, one major and twominor, or four
minor criteria are fulﬁlled.50 A deﬁnitive diagnosis can be
challenging, in part owing to phenotypic overlap with other
genetic and acquired cardiomyopathies.
ARVC is commonly described as a disease of the
desmosome, a multiprotein complex that forms cell-to-cell
junctions and links intermediate ﬁlaments of adjacent cells,jmd.amjpathol.org - The Journal of Molecular Diagnostics
Figure 1 Cellular locations of proteins involved
in inherited cardiomyopathies. Structural components
of the myocyte that are impacted by cardiomyopathy
include the sarcomere, Z-disk, nuclear lamina
proteins, intermediateﬁlaments, thedesmosome, and
the dystrophin-associated glycoprotein complex.
Genes linked to cardiomyopathy and the locations of
their protein products are indicated. Adapted with
permission from the American Society for Clinical
Investigation.33
Genetic Testing for Cardiomyopathiesthereby establishing a functional intercellular network.
Desmosomes are especially prevalent in tissues that are
subjected to mechanical stress, such as cardiac muscle or
skin, which explains why the phenotypic spectrum of
ARVC encompasses cardiac and skin manifestations (see
Genetic Etiology and Clinical Testing below). Molecular
mechanisms of ARVC include impaired cell-cell adhesion
and defective transmission of the contractile force.51 Recent
evidence suggests that ﬁbroadiposis is associated with
impaired WNT signaling, which leads to a redirection of
myocyte fate to adipocyte fate.51
Genetic Etiology and Clinical Testing
Most pathogenic ARVC variants are present in ﬁve genes
encoding desmosomal proteins [plakoglobin (JUP), desmo-
plakin (DSP), desmocollin-2 (DSC2), desmoglein-2 (DSG2),
and plakophilin-2 (PKP2)].52 In addition, homozygous or
compound heterozygous DSP and JUP variants have beenThe Journal of Molecular Diagnostics - jmd.amjpathol.orgdescribed in patients with cardiomyopathy (DCM or ARVC),
wooly/kinky hair, and palmoplantar hyperkeratosis (Naxos
and Carvajal syndromes53).
A few nondesmosomal ARVC genes have been described,
including the transmembrane protein 43 (TMEM43). Al-
though the evidence linking this gene to ARVC is strong,
only one pathogenic variant has been described.54 In
a recent study showing some evidence that variants in the
TTN gene may play a role in the etiology of ARVC, several
missense variants were identiﬁed and one segregated with
disease in multiple affected individuals.55 Other proposed,
although less convincing, ARVC genes include TGFb356
and RYR2, a gene associated with catecholaminergic poly-
morphic ventricular tachycardia.57
Analysis of the coding sequence of all desmosomal genes
will identify a variant in up to 50% of individuals with
ARVC, with w40% of cases carrying a pathogenic variant
in the PKP2 gene.52 Current guidelines recommend tar-
geted, variant-speciﬁc testing for family members when163
Teekakirikul et ala pathogenic variant has been identiﬁed in a proband but
rank the utility of comprehensive screening of the DSC2,
DSG2, DSP, JUP, and TMEM43 genes lower than the utility
of screening for HCM.4
Left Ventricular Noncompaction
Clinical Description and Disease Mechanism
Isolated LVNC is characterized by a heavily trabeculated or
spongy appearance of the LV myocardium. An arrest of
myocardial compaction during the ﬁrst trimester of embry-
onic development is widely believed to be a cause although
others have proposed that it can be an acquired process based
on case observations of LVNC after previous normal echo-
cardiographic ﬁndings (reviewed by Oechslin and Jenni58). A
recent literature survey suggests that LVNC is frequently
associated with mitochondrial disorders,59 followed by Barth
syndrome, an X-linked condition characterized by early-
onset cardiomyopathy (usually dilated, sometimes LVNC),
neutropenia, muscle weakness, and growth delay.
Although the true prevalence of LVNC is unknown,
reports range from 0.014% to 1.3% (reviewed by Oechslin
and Jenni58). Patients with LVNC tend to have early-onset
disease, with clinical expression varying from asymptom-
atic to progressively poor cardiac function, ventricular
hypertrophy, increased thromboembolic events, and SCD.60
The left ventricle is typically affected, but 50% of patients
with LVNC also have right ventricular involvement.61,62
Clinical manifestations and radiographic ﬁndings in LVNC
can resemble those identiﬁed in DCM and can occur in
conjunction with DCM or HCM in the same affected indi-
vidual or family (reviewed by Oechslin and Jenni58). There is
ongoing controversy about whether LVNC is a distinct
clinical entity. TheWorld Health Organization lists LVNC as
an unclassiﬁed cardiomyopathy,63 as does a position state-
ment from the European Society of Cardiology.64 On the
other hand, the American Heart Association classiﬁed LVNC
as a primary genetic cardiomyopathy in 2006.65
Genetic Etiology and Clinical Testing
Because LVNC is rare, its genetic etiology is not well
understood. Variants have been described in known DCM
and HCM genes encoding components of the sarcomere
(ACTC1, MYH7, MYBPC3, and TNNT2),66e68 the Z-disk
(LDB3),69,70 the nuclear lamina (LMNA),71 the dystrophin-
associated glycoprotein complex (DTNA),72 as well as the
Barth syndrome gene tafazzin (TAZ), a nuclear-encoded
mitochondrial protein.73 Of note, the NKX2.5 gene (which
encodes a cardiac speciﬁc transcription factor) had been
implicated in the etiology of LVNC based on its presence in
chromosomal region deleted in a girl with complex heart
disease.74 However; to date, no date no pathogenic variants
in NKX2.5 have been detected in individuals with isolated
LVNC.164The role of genetic testing in patients with LVNC received
the lowest grade based on the guideline published by theHeart
Failure Society of America, recommending only variant-
speciﬁc genetic testing for at-risk family members if a patho-
genic LVNC variant is identiﬁed in the proband.4 Genetic
testing is available simply because all genes associated with
LVNC are also involved in other cardiomyopathies, for which
testing has been more widely adopted. Detection rates have
not yet been well deﬁned and are currently restricted to iso-
lated reports. In the Laboratory for Molecular Medicine,
Partners HealthCare Center for Personalized Genetic Medi-
cine, diagnostic testing of a broad referral population detected
a clinically signiﬁcant variant (classiﬁed as likely pathogenic
or pathogenic) in 24% of 108 individuals with reported
LVNC. Variants were present in MYH7 (13.6%), MYBPC3
(4.0%), TNNI3 (2.0%), VCL (2.8%), TAZ (1.1%), and TNNT2
(1.0%). (B. Funke, unpublished data). Splice variants in the
MYH7 gene, which are exceedingly rare in HCM and DCM,
seem to be more prevalent in patients with LVNC68 (B.
Funke, unpublished observations).
Restrictive Cardiomyopathy
RCM is characterized by increased stiffness of the ventric-
ular chambers, although ventricular wall thickness and
systolic function is generally within normal limits. Most
individuals with RCM develop heart failure and succumb to
death within a few years.75 Some reports suggest a clinical
overlap between RCM and HCM.75e77
Idiopathic RCM is rare, and its genetic etiology is only
beginning to be deﬁned. Recent studies report variants in
sarcomere protein genes, including TNNI3, TNNT2, MYH7,
and ACTC1.77e80 In addition, missense variants in the
desmin gene (DES) have been identiﬁed in several families
with desmin-related myopathy, which can present with
RCM.81 Similar to LVNC, current Heart Rhythm Society/
European Heart Rhythm Association guidelines recommend
variant-speciﬁc genetic testing for at-risk family members
after the identiﬁcation of a pathogenic variant in the
proband.4
In the Laboratory for Molecular Medicine, Partners
HealthCare Center for Personalized Genetic Medicine,
diagnostic testing of a broad referral population detected
a clinically signiﬁcant variant in 35% of 50 individuals with
reported RCM.Variants were present in TNNI3 (18%),MYH7
(14%), and MYBPC3 (2%) (B. Funke, unpublished data).
Genetic and Phenotypic Overlap between
Inherited Cardiomyopathies
Cardiomyopathies have traditionally been deﬁned based
solely on clinical features, including ventricular morphology
and function. Although HCM, DCM, and ARVC are gen-
erally recognized as distinct clinical entities, there is an
increasing realization of substantial genetic and phenotypicjmd.amjpathol.org - The Journal of Molecular Diagnostics
Genetic Testing for Cardiomyopathiesoverlap. As described in the preceding sections, phenotypic
overlap exists between end-stage HCM and DCM82 and
between DCM and ARVC (which can manifest with
ventricular dilatation and can have LV involvement).47
Furthermore, features of LVNC can overlap with those of
HCM, DCM, and RCM (reviewed by Oechsline and Jenni58).
As the underlying genetic etiologies of these disorders are
being elucidated, substantial and increasing overlap emerges
(Table 1). For example, pathogenic sarcomere variants have
been primarily identiﬁed in patients with HCM but, more
recently, also in patients with DCM, LVNC, and RCM.
Z-disk genes have been implicated in DCM and in HCM.83
Desmosomal protein genes were initially thought to be
involved only in ARVC, but recent evidence suggests that
variants in these genes may also cause DCM.84 The pheno-
typic spectrum of variants in the desmin gene includes DCM,
RCM, and, most recently, ARVC.85e87 Finally, variants in
the TTN gene were recently shown to be a frequent cause of
DCM, but emerging evidence also associates this gene with
ARVC.55
Although it is clear that variants in a given gene can cause
more than one cardiomyopathy, it has been debated whether
the responsible variants are distinct. Some studies have iden-
tiﬁed the same variant in patients with HCM and in patients
with DCM and have attributed this to phenotypic plas-
ticity.35,88 However, the molecular mechanisms underlying
HCM (increased contractility) and DCM (decreased contrac-
tility) are fundamentally different, which calls into question
whether the same variant can truly cause both diseases.
Functional characterization of several HCM and DCM vari-
ants indeed showed fundamentally opposite properties, sup-
porting distinct variant spectra,89e92 as reviewed by Ashraﬁan
and Watkins.93 Assuming nonoverlapping variant spectra, the
identiﬁcation of HCM variants in patients with marked LV
dilatation and impaired systolic function may, therefore,
reﬂect end-stage remodeling of HCM rather than primary
DCM. Another explanation for the identiﬁcation of one and
the same variant in diseases with different molecular mecha-
nisms is that these are not the primary cause of disease but act
as modiﬁers or are completely benign. We are only now
beginning to appreciate the spectrum of rare benign variation,
as it is beginning to be possible to query thousands of
sequenced genomes and exomes (1000 Genomes Project,
National Heart, Lung, and Blood Institute Exome Sequencing
Project). These data sets have made it all too clear that in the
past, many studies inferred pathogenicity based on insufﬁcient
evidence. This has recently been demonstrated for a large
number of published variants that were reported as causative
of DCM.94 One example illustrating a variant’s journey is the
Ala833Thr variant inMYBPC3, whichwas initially reported in
four probands with HCM and in 1 in 400 control individ-
uals.18,95,96 The presence in a single control individual was
regarded as insufﬁcient to rule out a pathogenic role, as
reduced penetrance is not uncommon in HCM. Today, we
know that this variant is present in 12 of 6952 chromosomes
(0.17%; National Heart, Lung, and Blood Institute ExomeThe Journal of Molecular Diagnostics - jmd.amjpathol.orgSequencing Project), illustrating the power of large genome
sequencing studies and strongly suggesting that this variant is
unlikely a primary cause of disease.
In summary, it seems likely that individual variants are
most often speciﬁc to one cardiomyopathy presentation.
However, further studies including careful phenotypic
analysis and variant classiﬁcation are necessary to establish
this with certainty.Genetic Testing for Inherited Cardiomyopathies
in the Postgenomic Era
Until recently, comprehensive genetic testing for genetically
heterogeneous diseases, such as inherited cardiomyopathies,
was difﬁcult. The high cost of traditional (Sanger) sequencing
technology led to gene panels of limited size that typically did
not accommodate genes with low detection rates. NGS
technologies have now completely eliminated this limitation
such that virtually any gene with a published association with
the disease of interest can be tested. Whole exome and whole
genome sequencing (WES/WGS) are the ultimate genetic
tests, and early success stories provide a taste of their power.97
However, the technical quality of WES/WGS is still subop-
timal as coverage of essential genes cannot be guaranteed. In
addition, despite the rapidly dropping cost of running the
assay, the analysis of the enormous number of variants
detected is still too complex to broadly offer WES/WGS,
particularly when the clinical diagnosis is clear. For these
reasons and at the time of writing this review, targeted NGS
tests may be better ﬁrst-line tests for patients with well-
established clinical diagnoses. On the other hand, when this
type of testing is negative or when a clinical diagnosis is
ambiguous, WES/WGS are powerful tools and are being
increasingly used in clinical practice.
Targeted NGS-based gene panels for inherited cardiomy-
opathies are offered by a growing number of laboratories in
the United States and worldwide (http://www.genetests.org
and http://www.ncbi.nlm.nih.gov/gtr). Although these
panels are an order of magnitude smaller than WES/
WGSebased testing (w50 to 100 genes), they are based on
the same novel paradigm that the laboratory assay performed
can include genes for more than one disease. The test ordered
by the health care provider now becomes a virtual entity,
triggering the analysis of speciﬁc sets of genes depending on
the patient’s diagnosis. This design provides optimal ﬂexi-
bility by enabling simultaneous screening of several sets of
genes when the clinical diagnosis is uncertain but retains the
option of analyzing disease-speciﬁc gene sets when the
diagnosis is clear. This eliminates the costly and lengthy
stepwise testing process that has dominated genetic testing
for cardiomyopathies for a decade.
Despite these obvious advantages, NGS testing has some
important limitations. In the past, the limited size of gene
panels provided a natural selection for well-established
disease genes with high detection rates. As this restriction165
Teekakirikul et alhas been removed, it has become critical to carefully review
the scientiﬁc evidence underlying a proclaimed disease gene.
Genes with low detection rates are typically supported by
a limited number of studies. In addition, many studies infer
disease association based on a small number of variants and
limited evidence, such as absence from a small number of
healthy control individuals and evolutionary conservation of
the affected amino acid. It has been estimated that screening
300 chromosomes identiﬁes only 80% of all rare benign
variation and that 6000 chromosomes are necessary to
identify the full spectrum.98 It is, therefore, not surprising that
many cardiomyopathy variants initially published as causa-
tive turn out to be present at low frequencies in large exome
sequencing data sets.94 Additional genetic evidence, such as
segregation with disease and functional data that would lend
stronger support, is not easy to generate and is rarely avail-
able. In vitro functional data are frequently provided but have
to be interpreted with caution as it may or may not translate
into a clinical phenotype in humans. When critically evalu-
ated, many cardiomyopathy genes are better classiﬁed as
candidate genes. Table 1 lists established and proposed
cardiomyopathy genes and classiﬁes each gene into one of
three levels of supporting evidence. Clinical sequencing of
candidate genes that have not yet been ﬁrmly associated with
disease can lead to an inﬂation of VUSs and, therefore, to an
increased likelihood of receiving an inconclusive test result
when no clearly pathogenic variant is present among the
detected variants.The Emerging Role of Molecular Diagnostic
Testing Laboratories
Sequencing a large enough number of patient samples to
deﬁnitively prove a disease association is difﬁcult for any
individual study, especially for genes with very low detection
rates. In contrast, molecular diagnostic testing laboratories
have the ability to accrue larger numbers of tested patients and
can help shed light on the role of newly emerging disease
genes. During the past decade, many laboratories have begun
to populate this gray zone between clinical research and
molecular diagnostic testing. Although testing laboratories
typically do not have access to detailed clinical information,
the sheer number of patients tested can help validate (or refute)
published claims for a disease association. It is increasingly
common that the genetic testing process involves a close
collaboration between molecular geneticists and genetic
counselors at the testing laboratory and the referring health
care provider and the family. Genetic test results often initiate
a cascade of events, including familial segregation studies and
iterative reevaluation of clinical and molecular evidence, to
determine the clinical signiﬁcance of novel variants.
Although clinical sequencing of emerging disease genes is
increasingly performed, it is important to realize that it can
take years until the spectrum of pathogenic and benign vari-
ation has been characterized. Until then, testing often yields166many VUSs, and these inconclusive results can be problem-
atic for the patient.99 The rapidly increasing number of
sequenced genomes is beginning to remedy this problem, as
the spectrum of rare benign variation is better deﬁned.
However, several challenges remain. First, the lack of avail-
able clinical annotation for these cohorts can be problematic
because reduced penetrance and late-onset disease is common
for most cardiomyopathies. Therefore, very rare variants
remain difﬁcult to interpret as a presymptomatic status of the
carrier cannot be excluded. Furthermore, the Single Nucleo-
tide Polymorphism Database (dbSNP) is now well-known to
contain clinically signiﬁcant variants as more rare variation is
deposited from broad populations and only some are
adequately labeled as clinically signiﬁcant. Finally, large-
scale exome/genome sequencing efforts are still limited to
a few ethnic groups, and the spectrum of common variants
remains poorly deﬁned for many minority populations.Conclusions and Outlook
Testing for genetically heterogeneous cardiac disorders,
such as inherited cardiomyopathies, has been challenging
owing to several factors. First, the high cost of traditional
sequencing technologies posed a severe limitation to the
research and discovery of new disease genes and to the
number of known disease genes that could be tested
simultaneously in a clinical setting. In addition, although
genetic testing has been recognized to be useful for pre-
dictive testing, our incomplete understanding of the spec-
trum of pathogenic variants and the high discovery rate
of novel VUSs continue to limit the clinical utility of
available tests. Finally, knowledge that cardiomyopathies
have a signiﬁcant genetic etiology has not yet been widely
disseminated, especially for DCM, which was long believed
to be mainly the result of environmental lesions.
Recent technological breakthroughs have now paved the
way for the expanding adoption of genetic testing in clinical
practice and the medical management of patients. NGS
technologies have increased the size of genetic testing
panels by an order of magnitude, and the $1000 genome,
which was unthinkable just 10 years ago, is now within
reach. These developments are expected to radically change
the landscape of medical genetic testing as we know it
today. It is likely that with rapidly dropping test costs and
increasing accuracy, WGS eventually will replace most, if
not all, currently offered genetic tests. However, because the
timely and accurate interpretation of thew3 million variants
present per genome is still challenging, WGS is currently
used only for highly selected, clinically complex cases.
Success stories where WGS identiﬁed the cause of such
diagnostically challenging cases are inspiring and give an
outlook to what will be common in the relatively near
future. As we are beginning to sequence many genomes, we
will undoubtedly identify genetic etiologies for inherited
cardiomyopathies that have been elusive thus far.jmd.amjpathol.org - The Journal of Molecular Diagnostics
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